18 CONFIDENTIAL | --- | --- | |-------------------------------------|-------| | | | | Stratification Factors: | | | • Disease Location | | | (bone only vs. visceral) • Region | | PARCE SENICS MGD024 is investigational and has not yet been approved for marketing by any regulatory authority MACRO GENICS MGD024 MGD024: Favorable Cytokine Profile, Encouraging Combination Activity (in vivo) Improved Tolerability vs. Wild Type (WT) in Cynos 21 Preclinical data presented at ASH 2021 Interleukin-6 MGD024 Enhances A ...

Company Participants Operator Thank you, operator. Good afternoon. And welcome to MacroGenics conference call to discuss our first quarter 2023 financial and operational results. For anyone who's not had the chance to review these results, we issued a press release this afternoon outlining today's announcement, which is available under the Investors tab on our Web site at macrogenics.com. You may also listen to this conference call via webcast on our Web site, where it will be archived for 30 days beginning ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC. (Exact name of registrant as specified in its charter) Delaware 06-1591613 (State or other jurisdiction of (I.R.S. ...

Developing Breakthrough Biologics, Life-changing Medicines® 2 DART, TRIDENT, MacroGenics, the MacroGenics logo and MARGENZA are trademarks or registered trademarks of MacroGenics, Inc. All third-party trademarks used herein are registered trademarks of their respective owners. Integrated approach for exploiting direct and immune-based killing mechanisms Proof-of-Concept (Phase 2) Major Market Rights | --- | --- | --- | --- | --- | |--------------------------------|----------------------------------|-------- ...

Our expected funding requirements reflect anticipated expenditures related to the Phase 2 TAMARACK clinical trial, the planned Phase 2 study of lorigerlimab and metastatic castration resistant prostate cancer, that Scott will tell you about momentarily, as well as our other clinical and preclinical studies currently ongoing. Of course, we believe the best is yet to come and have high hopes for our proprietary pipeline of product candidates, which I will now walk you through. Before I describe our data, I wi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36112 MACROGENICS, INC. (Exact name of registrant) Delaware 06-1591613 (State of organization) (I.R.S. Employer Identification Number ...

MacroGenics, Inc. (NASDAQ:MGNX) Q3 2022 Results Conference Call November 3, 2022 4:30 PM ET Company Participants Jim Karrels - SVP and CFO Dr. Scott Koenig - President and CEO Conference Call Participants Jessica Hui - Evercore Jonathan Chang - SVB Securities David Dai - SMBC Charles Zhu - Guggenheim Partners Silvan Tuerkcan - JMP Securities Operator Good afternoon. We will begin the MacroGenics 2022 Third Quarter Corporate Progress and Financial Results Conference Call in just a moment. [Operator Instructi ...

MacroGenics, Inc. (NASDAQ:MGNX) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Chris James - VP, IR and Corporate Communications Scott Koenig - President and CEO Jim Karrels - CFO Conference Call Participants Jon Miller - Evercore ISI David Dai - SMBC Stephen Willey - Stifel Etzer Darout - BMO Capital Markets Faisal Khurshid - SVB Securities Operator Good afternoon. We will begin the MacroGenics' 2022 Second Quarter Corporate Progress and Financial Results Conference Call in ...

MacroGenics, Inc. (NASDAQ:MGNX) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Chris James - Vice President, Investor Relations and Corporate Communications Scott Koenig - President and Chief Executive Officer Jim Karrels - Chief Financial Officer Conference Call Participants Jonathan Chang - SVB Securities Kaveri Pohlman - BTIG Etzer Darout - BMO Capital Markets Peter Lawson - Barclays Stephen Willey - Stifel Jonathan Miller - Evercore ISI Yigal Nochomovitz - Citigroup David D ...

® Developing Breakthrough Biologics, Life-changing Medicines® Corporate Update February 24, 2022 The information in this slide deck is current as of February 24, 2022, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics' Annual, Quarterly and Current Reports filed with the SEC. MacroGenics undertakes no obligation to update any of the information herein. Cautionary Note on Forward-Looking Statements 2 Legal Notices Any statements in these materials about future expectations, ...